DTCF.F logo

Defence Therapeutics OTCPK:DTCF.F Stock Report

Last Price

US$0.44

Market Cap

US$20.0m

7D

-1.5%

1Y

-72.3%

Updated

15 Jan, 2025

Data

Company Financials

Defence Therapeutics Inc.

OTCPK:DTCF.F Stock Report

Market Cap: US$20.0m

DTCF.F Stock Overview

Develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. More details

DTCF.F fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Risk Analysis

Earnings have declined by 45.4% per year over past 5 years

Negative shareholders equity

Makes less than USD$1m in revenue (CA$0)

Shares are highly illiquid

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Defence Therapeutics Inc. Competitors

Aprea Therapeutics

NasdaqCM:APRE

US$19.7m

Bolt Biotherapeutics

NasdaqCM:BOLT

US$19.7m

Tenax Therapeutics

NasdaqCM:TENX

US$21.9m

GeoVax Labs

NasdaqCM:GOVX

US$19.9m

Price History & Performance

Summary of share price highs, lows and changes for Defence Therapeutics
Historical stock prices
Current Share PriceCA$0.44
52 Week HighCA$1.74
52 Week LowCA$0.27
Beta1.18
1 Month Change7.16%
3 Month Change8.13%
1 Year Change-72.31%
3 Year Change-88.76%
5 Year Changen/a
Change since IPO-82.28%

Recent News & Updates

Recent updates

Shareholder Returns

DTCF.FUS BiotechsUS Market
7D-1.5%-1.8%0.7%
1Y-72.3%-7.0%25.3%

Return vs Industry: DTCF.F underperformed the US Biotechs industry which returned -8.4% over the past year.

Return vs Market: DTCF.F underperformed the US Market which returned 23.2% over the past year.

Price Volatility

Is DTCF.F's price volatile compared to industry and market?
DTCF.F volatility
DTCF.F Average Weekly Movementn/a
Biotechs Industry Average Movement11.2%
Market Average Movement6.5%
10% most volatile stocks in US Market18.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: DTCF.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine DTCF.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017n/aSebastien Plouffedefencetherapeutics.com

Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; ARM-X vaccine program, a mesenchymal stem cell-based vaccine targeting cancer; and mRNA vaccination program. It also offers Accuvac for dendritic cell cancer vaccines; a protein-based vaccine formulation against COVID and infectious diseases; and cervical cancer vaccine.

Defence Therapeutics Inc. Fundamentals Summary

How do Defence Therapeutics's earnings and revenue compare to its market cap?
DTCF.F fundamental statistics
Market capUS$20.00m
Earnings (TTM)-US$8.10m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.7x

P/E Ratio

Is DTCF.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DTCF.F income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other ExpensesCA$11.60m
Earnings-CA$11.60m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.24
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-44.0%

How did DTCF.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/15 13:15
End of Day Share Price 2025/01/15 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Defence Therapeutics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution